Targeting oncogene AKT1 for novel oral cancer therapy
| Project/Area Number |
21592557
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Surgical dentistry
|
|---|
| Research Institution | Ehime University |
|---|
Principal Investigator |
NAKASHIRO Koichi 愛媛大学, 大学院・医学系研究科, 准教授 (90314880)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2011: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2010: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2009: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 口腔癌 / AKT1 / RNA干渉 / siRNA / 分子標的治療 |
|---|
| Research Abstract |
Synthetic small interfering RNA targeting oncogene Akt1(siAkt1) was specifically delivered human oral squamous cell carcinoma(OSCC) xenografted tumors by atelocollagen-mediated systemic administration. Furthermore, we showed the usefulness of serum osteopontin and in vitro sensitivity test to predict the clinical effect of siAkt1. These results suggest that Akt1 functions as a critical oncogene in human OSCC cells and targeting Akt1 appears a novel approach for treatment with oral cancer.
|
Report
(4 results)
Research Products
(29 results)
-
-
-
-
-
-
-
-
-
[Journal Article] Knockdown of Akt isoforms by RNA silencing suppresses the growth of human prostate cancer cells in vitro and in vivo2010
Author(s)
Sasaki T, Nakashiro K, Tanaka H, Azuma K, Goda H, Hara S, Onodera J, Fujimoto I, Tanji N, Yokoyama M, Hamakawa H.
-
Journal Title
Biochem Biophys Res Commun
Volume: 399
Pages: 79-83
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
